| Naptumomab estafenatox | TTS-CD3; ABR-217620 | Phase 2 Clinical | Active Biotech Ab | Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Melanoma; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
| ALG.APV-527 | ALG.APV 527; ADC-1016; ATOR-1016; ALG.APV-527; ALG-APV-527 | Phase 2 Clinical | Alligator Bioscience Ab, Aptevo Therapeutics Inc | | Details |
| JK-06 | JK-06 | Phase 2 Clinical | Xinlitai (Chengdu) Biological Technology Co Ltd | | Details |
| TUB-030 | TUB-030 | Phase 2 Clinical | Tubulis GmbH | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| ACR-246 | ACR246; ACR-246; ADC2154; ADC-2154 | Phase 2 Clinical | Hangzhou Adcoris Biopharmacy Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Uterine Cervical Neoplasms | Details |
| IBR-854 | IBR854; IBR-854 | Phase 2 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Solid tumours | Details |
| SYD-1875 | SYD-1875 | Phase 1 Clinical | Synthon Bv | | Details |
| ASN-004 | ASN-004 | Phase 1 Clinical | Asana Biosciences Llc | | Details |
| anti-5T4 CAR NK-cell therapy (Wuxi Peapole's Hospital/Hangzhou Yingbairui Biomedical Technology) | | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | | Details |
| Naptumomab estafenatox/Durvalumab | NTX-352 | Phase 1 Clinical | Neotx Therapeutics Ltd | | Details |
| XB-010 | XB-010 | Phase 1 Clinical | Exelixis Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| FTL-008.16 | FTL-008.16; FTL008.16 | Phase 1 Clinical | Sound(Chengdu)Biopharmacauticals Co Ltd | | Details |
| CBA-1535 | CBA-1535 | Phase 1 Clinical | Chiome Bioscience Inc | Carcinoma, Non-Small-Cell Lung; Mesothelioma; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms | Details |
| Anti-5T4 CAR-raNK Cell Therapy | | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | | Details |
| Prostate cancer vaccine(inactivated viral)(University of Oxford) | | Clinical | University Of Oxford | | Details |
| 68Ga-NOTA-H006 | | Clinical | Huashan Hospital | | Details |
